Did a projector cast onto Trump Tower a cartoon of Border Patrol commander Greg Bovino spilling blood? No, that's not true: ...

Markets got yet another weekend surprise from the Trump administration on Sunday, with news that the Justice Department is threatening to indict Federal Reserve Chair Jerome Powell over comments made ...

HOUSTON, Texas (KTRK) -- Derwin Graham runs in hopes to inspire people of color to get moving, bringing that message directly to the community. Throughout the week, you can see members of Space City ...

ChatGPT's web traffic has decreased since November, when Google launched Gemini 3. Gemini traffic increased by 28% month-over-month in December, while ChatGPT's traffic decreased by 5.6%, per ...

XRP slid to $2.27 after breaking below $2.32 support, but a high-volume flush into $2.21 drew bids and stabilized the move — leaving traders focused on whether the bounce can reclaim $2.31-$2.32 or if ...

The two points dropped threaten to be critical but can the immediate damage to the title race be offset by the return of one man? What about if that player's peak is Ballon d'Or level? Enzo ...

The NCAA transfer portal has opened, and with it comes a rush of narratives as players begin to make official visits and find their new homes. The Auburn Tigers, who’ve now seen over 30 players depart ...

The food and beverage giant is aiming to lean into simpler ingredients and "functional benefits" starting in 2026 Angus Mordant/Bloomberg via Getty PepsiCo, parent company to over 60 brand-name food ...

PepsiCo is preparing to pull nearly a fifth of its U.S. products off shelves as part of an overhaul designed to simplify its snack portfolio, redirect investment and jump-start growth heading into ...

Two-year follow up from Arm 8 of the EPCORE NHL-2 trial (abstract 64) showed fixed-duration epcoritamab plus rituximab plus dose-attenuated cyclophosphamide, doxorubicin, vincristine, and prednisone ...

Genmab A/S (Nasdaq: GMAB) today announced updated results from two ongoing clinical trials evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging antibody administered ...